Cancer Research AACR Conference on Molecular Diagnostics - 2008  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 35, 144-155, January 1, 1975]
© 1975 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicolson, G. L.
Right arrow Articles by Hunter, T. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicolson, G. L.
Right arrow Articles by Hunter, T. R.

Mechanism of Cell Entry and Toxicity of an Affinity-purified Lectin from Ricinus communis and Its Differential Effects on Normal and Virus-transformed Fibroblasts1

Garth L. Nicolson2, Monique Lacorbiere and Tony R. Hunter3

Departments of Cancer Biology [G. L. N., M. L.] and Tumor Virology [T. R. H.]. The Salk Institute for Biological Studies, San Diego, California 92112

An affinity-purified plant lectin from Ricinus communis (RCAII) was shown to exhibit differential toxicity toward SV40-transformed 3T3 fibroblasts grown in vitro. When macromolecular synthesis was examined in SV3T3 and 3T3 cells, RCA11 suppressed cell protein synthesis in the transformed line at lower concentrations (1/50 to 1/100) compared to the 3T3 line, and these effects were blocked by the RCAII inhibitors D-galactose or lactose. RNA and DNA synthesis and L-leucine transport were relatively unaffected by RCAII concentrations (>1 µg/ml) that completely suppressed protein synthesis in both cell lines. The RCAII-mediated inhibition of cell protein synthesis required incubation times longer than 60 min, but quantitative cell binding studies with 125I-RCAII indicated that the lectin binds to maximal levels in approximately 5 to 10 min, even at 4°. During 10-min labeling experiments with 125I-RCAII (1 µg/ml), it was demonstrated that the cell-bound lectin could be almost quantitatively removed from cells up to an additional 15 min after labeling without subsequent inhibition of protein synthesis. However, longer incubation times (> 30 min) after RCAII cell labeling and washing resulted in incomplete removal of cell-bound lectin (less than 20 to 30% of cell-bound lectin could be removed after a 60-min incubation). The longer incubation times (>60 min) also resulted in almost complete inhibition of protein synthesis. Ferritin-conjugated RCAII (ferritin-RCAII) was used to follow the fate of the cell-bound lectin. Ferritin-RCAII bound rapidly (<10 min) to SV3T3 cell surfaces and could be blocked from labeling with lactose. After a 10-min incubation at 4° in ferritin-RCAII solutions, the ferritin label was exclusively located at the extracellular surface in a random distribution. After washing and incubation at 37°, the ferritin-RCAII induced clustering of its receptors (~15 to 30 min) and eventually induced endocytosis (~30 to 60 min). Further incubation (>60 min) resulted in a predominantly intracellular localization of ferritin-RCAII inside endocytotic vesicles and free in the cell cytoplasm. That RCAII acts directly on protein synthesis after cell entry was confirmed with rabbit reticulocyte and mouse Krebs II ascites S30 cell-free protein synthesis systems. Concentrations of RCAII (0.1 to 1 µg/ml) that inhibit cell protein synthesis in 90 min act within 1 to 3 min to suppress cell-free protein synthesis. The saccharide prevention of RCAII inhibition of cell, but not cell-free, protein synthesis indicates that different sites may be involved in cell binding and inhibition of protein synthesis. These results suggest that RCAII-mediated toxicity occurs by the following sequence of events: (a) cell surface binding; (b) lectin-induced surface clustering of RCAII receptors; (c) endocytosis of RCAII; (d) release of RCAII from inside endocytotic vesicles into the cell cytoplasm; and (e) direct RCAII interaction and inactivation of protein synthesis. The similarity between RCAII, its mode of action, and the phytotoxic ricin is discussed.

1 These studies were supported by NIH Grant CA-15122, National Cancer Institute Contract CB-33879 (Tumor Immunology Program), and National Science Foundation Grant GB-34178 (Human Cell Biology Program) and a grant from the Cancer Research Institute, Inc.

2 To whom correspondence should be addressed.

3 Present address: Department of Biochemistry, Cambridge University, Tennis Court Road, Cambridge, England.

Received 6/14/74. Accepted 10/ 3/74.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C.-L. Liu, C.-C. Tsai, S.-C. Lin, L.-I. Wang, C.-I. Hsu, M.-J. Hwang, and J.-Y. Lin
Primary Structure and Function Analysis of the Abrus precatorius Agglutinin A Chain by Site-directed Mutagenesis. Pro199 OF AMPHIPHILIC alpha -HELIX H IMPAIRS PROTEIN SYNTHESIS INHIBITORY ACTIVITY
J. Biol. Chem., January 21, 2000; 275(3): 1897 - 1901.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1975 by the American Association for Cancer Research.